Development pipeline


Non-Alcoholic Steato-Hepatitis (or NASH) is the most common chronic liver disorder in Western countries. It is a possible outcome of metabolic disorders such as obesity or type 2 diabetes. It is estimated that more than 5% of the population worldwide is affected by NASH, which main consequences are cirrhosis and hepato-cellular carcinoma.

Today, histological examination of the liver through a biopsy is required to diagnose NASH. Hence, the development of new non-invasive methods is a need recognized by health authorities, necessary for an improved patient care.

DIAFIR, develops NASHMIR®, a non-invasive test based on the metabolic signature of NASH, from a simple drop of serum, which aim to replace the current invasive procedure. Our patented technology combines the mid-infrared light blood serum recording and the machine learning algorithm diagnosis score delivery.


Acute septic arthritis is an inflammation of the synovial membrane of the joint resulting from an infection. The rapid progress of the pathology (within a few hours to a few days maximum) can lead to irreversible destruction of the joint tissues and even mortality in 10% of the cases in the event of a diagnostic delay, making septic arthritis a therapeutic emergency.

Although septic arthritis is rare, its management cost is significant: It requires a 48 hours minimum hospitalization for preventive antibiotic therapy, pending the results of the diagnosis based on the cytology of synovial fluid.

Diafir develops SYNOFAST®, a rapid diagnostic orientation test of septic arthritis cases, based on the mid-infrared spectroscopic analysis of the synovial fluid, allowing sepsis detection in less than 10 minutes. The result is a rapid management of patients at risk and avoid unnecessary hospitalization of the one which are not, and therefore a significant cost saving for health authorities.